• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Geographic variations in species distribution and echinocandin and azole antifungal resistance rates among Candida bloodstream infection isolates: report from the SENTRY Antimicrobial Surveillance Program (2008 to 2009).地理分布的差异和棘白菌素类与唑类抗真菌药物耐药率在血流感染念珠菌分离株中的表现：来自 SENTRY 抗菌药物监测计划的报告（2008 年至 2009 年）。
J Clin Microbiol. 2011 Jan;49(1):396-9. doi: 10.1128/JCM.01398-10. Epub 2010 Nov 10.
2
Candida bloodstream infections: comparison of species distribution and resistance to echinocandin and azole antifungal agents in Intensive Care Unit (ICU) and non-ICU settings in the SENTRY Antimicrobial Surveillance Program (2008-2009).念珠菌血流感染：重症监护病房（ICU）和非 ICU 环境下 SENTRY 抗菌监测计划（2008-2009 年）中，菌种分布和棘白菌素类及唑类抗真菌药物耐药性的比较。
Int J Antimicrob Agents. 2011 Jul;38(1):65-9. doi: 10.1016/j.ijantimicag.2011.02.016. Epub 2011 Apr 22.
3
Candida bloodstream infections: comparison of species distributions and antifungal resistance patterns in community-onset and nosocomial isolates in the SENTRY Antimicrobial Surveillance Program, 2008-2009.念珠菌血流感染：2008-2009 年 SENTRY 抗菌监测计划中社区获得性和医院获得性分离株的菌种分布和抗真菌药物耐药模式比较。
Antimicrob Agents Chemother. 2011 Feb;55(2):561-6. doi: 10.1128/AAC.01079-10. Epub 2010 Nov 29.
4
Candida and candidaemia. Susceptibility and epidemiology.念珠菌与念珠菌血症。药敏性与流行病学。
Dan Med J. 2013 Nov;60(11):B4698.
5
Variation in Candida spp. distribution and antifungal resistance rates among bloodstream infection isolates by patient age: report from the SENTRY Antimicrobial Surveillance Program (2008-2009).不同年龄段血流感染分离株中念珠菌属分布及抗真菌药物耐药率的变化：SENTRY 抗菌药物监测计划（2008-2009 年）的报告。
Diagn Microbiol Infect Dis. 2010 Nov;68(3):278-83. doi: 10.1016/j.diagmicrobio.2010.06.015. Epub 2010 Sep 16.
6
Echinocandin susceptibility testing of Candida isolates collected during a 1-year period in Sweden.在瑞典进行的为期一年的研究中，对收集到的念珠菌分离株进行棘白菌素药敏试验。
J Clin Microbiol. 2011 Jul;49(7):2516-21. doi: 10.1128/JCM.00201-11. Epub 2011 May 4.
7
Antifungal susceptibilities of Candida glabrata species complex, Candida krusei, Candida parapsilosis species complex and Candida tropicalis causing invasive candidiasis in China: 3 year national surveillance.中国引起侵袭性念珠菌病的光滑念珠菌种复合体、克柔念珠菌、近平滑念珠菌种复合体和热带念珠菌的抗真菌药敏性：3 年国家监测。
J Antimicrob Chemother. 2015 Mar;70(3):802-10. doi: 10.1093/jac/dku460. Epub 2014 Dec 3.
8
In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance.念珠菌属侵袭性分离株对阿尼芬净、卡泊芬净和米卡芬净的体外敏感性：六年全球监测
J Clin Microbiol. 2008 Jan;46(1):150-6. doi: 10.1128/JCM.01901-07. Epub 2007 Nov 21.
9
Geographic and temporal trends in isolation and antifungal susceptibility of Candida parapsilosis: a global assessment from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005.近平滑念珠菌的分离情况及抗真菌药敏的地理和时间趋势：2001年至2005年ARTEMIS DISK抗真菌监测项目的全球评估
J Clin Microbiol. 2008 Mar;46(3):842-9. doi: 10.1128/JCM.02122-07. Epub 2008 Jan 16.
10
Activity of a Long-Acting Echinocandin, Rezafungin, and Comparator Antifungal Agents Tested against Contemporary Invasive Fungal Isolates (SENTRY Program, 2016 to 2018).长效棘白菌素类药物雷扎芬净与其他抗真菌药物对当代侵袭性真菌分离株的活性检测（SENTRY 项目，2016 年至 2018 年）。
Antimicrob Agents Chemother. 2020 Mar 24;64(4). doi: 10.1128/AAC.00099-20.

引用本文的文献

1
Addressing the silent threat: managing invasive infections in hospitalized newborns.应对潜在威胁：管理住院新生儿的侵袭性感染
Front Pediatr. 2025 Jul 17;13:1613832. doi: 10.3389/fped.2025.1613832. eCollection 2025.
2
Effects of Ire1 gene on virulence and pathogenicity of .Ire1基因对……的毒力和致病性的影响。 （原文此处不完整，缺少具体对象）
Open Life Sci. 2025 Apr 29;20(1):20221062. doi: 10.1515/biol-2022-1062. eCollection 2025.
3
Biofilm-Associated Candidiasis: Pathogenesis, Prevalence, Challenges and Therapeutic Options.生物膜相关性念珠菌病：发病机制、患病率、挑战与治疗选择
Pharmaceuticals (Basel). 2025 Mar 25;18(4):460. doi: 10.3390/ph18040460.
4
: Multidrug Resistance and Increased Virulence in a Major Opportunistic Fungal Pathogen.一种主要机会性真菌病原体中的多药耐药性与毒力增强
Curr Fungal Infect Rep. 2012 Jun;6(3):154-164. doi: 10.1007/s12281-012-0091-0.
5
Nineteen years retrospective analysis of epidemiology, antifungal resistance and a nomogram model for 30-day mortality in nosocomial candidemia patients.医院念珠菌血症患者的流行病学、抗真菌耐药性及30天死亡率列线图模型的19年回顾性分析
Front Cell Infect Microbiol. 2025 Feb 3;15:1504866. doi: 10.3389/fcimb.2025.1504866. eCollection 2025.
6
CO potentiates echinocandin efficacy during invasive candidiasis therapy via dephosphorylation of Hsp90 by Ptc2 in condensates.在侵袭性念珠菌病治疗期间，一氧化碳通过凝聚物中Ptc2对Hsp90的去磷酸化作用增强棘白菌素的疗效。
Proc Natl Acad Sci U S A. 2025 Feb 11;122(6):e2417721122. doi: 10.1073/pnas.2417721122. Epub 2025 Feb 5.
7
Fungal Infections, Treatment and Antifungal Resistance: The Sub-Saharan African Context.真菌感染、治疗与抗真菌耐药性：撒哈拉以南非洲地区的情况
Ther Adv Infect Dis. 2024 Nov 13;11:20499361241297525. doi: 10.1177/20499361241297525. eCollection 2024 Jan-Dec.
8
Candidaemia: A 9-Year Retrospective Analysis of Epidemiology and Antimicrobial Susceptibility in Tertiary Care Hospitals in Western China.念珠菌血症：中国西部三级医院9年流行病学及抗菌药物敏感性回顾性分析
Infect Drug Resist. 2024 Sep 5;17:3891-3900. doi: 10.2147/IDR.S477815. eCollection 2024.
9
Antifungal heteroresistance causes prophylaxis failure and facilitates breakthrough Candida parapsilosis infections.抗真菌异质性耐药导致预防治疗失败，并促进了近平滑念珠菌感染的突破。
Nat Med. 2024 Nov;30(11):3163-3172. doi: 10.1038/s41591-024-03183-4. Epub 2024 Aug 2.
10
Insights from Three Pan-European Multicentre Studies on Invasive Candida Infections and Outlook to ECMM Candida IV.三项关于侵袭性念珠菌感染的泛欧多中心研究的见解及欧洲临床微生物与感染病学会念珠菌IV会议展望
Mycopathologia. 2024 Aug 1;189(4):70. doi: 10.1007/s11046-024-00871-0.

本文引用的文献

1
Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria.重新审视棘白菌素类药物和念珠菌的临床折点：整合分子、临床和微生物学数据，以制定出基于物种的解释标准。
Drug Resist Updat. 2011 Jun;14(3):164-76. doi: 10.1016/j.drup.2011.01.004. Epub 2011 Feb 24.
2
Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: time for harmonization of CLSI and EUCAST broth microdilution methods.氟康唑和念珠菌的野生型 MIC 分布、流行病学折点值和种特异性临床断点：CLSI 和 EUCAST 肉汤微量稀释方法协调的时机。
Drug Resist Updat. 2010 Dec;13(6):180-95. doi: 10.1016/j.drup.2010.09.002. Epub 2010 Nov 2.
3
Candidaemia associated with decreased in vitro fluconazole susceptibility: is Candida speciation predictive of the susceptibility pattern?与氟康唑体外敏感性降低相关的念珠菌血症：念珠菌种属是否可预测药敏模式？
J Antimicrob Chemother. 2010 Jul;65(7):1460-5. doi: 10.1093/jac/dkq136. Epub 2010 Apr 29.
4
Breakthrough invasive candidiasis in patients on micafungin.米卡芬净治疗患者发生突破性侵袭性念珠菌病。
J Clin Microbiol. 2010 Jul;48(7):2373-80. doi: 10.1128/JCM.02390-09. Epub 2010 Apr 26.
5
Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-year analysis of susceptibilities of Candida Species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion.ARTEMIS DISK 全球抗真菌监测研究结果，1997 年至 2007 年：10.5 年时间内通过 CLSI 标准化纸片扩散法测定的念珠菌属对氟康唑和伏立康唑的药敏性分析。
J Clin Microbiol. 2010 Apr;48(4):1366-77. doi: 10.1128/JCM.02117-09. Epub 2010 Feb 17.
6
Novel FKS mutations associated with echinocandin resistance in Candida species.新型 FKS 突变与棘白菌素类耐药的念珠菌属相关。
Antimicrob Agents Chemother. 2010 May;54(5):2225-7. doi: 10.1128/AAC.00998-09. Epub 2010 Feb 9.
7
Epidemiology of invasive mycoses in North America.北美洲侵袭性真菌病的流行病学。
Crit Rev Microbiol. 2010;36(1):1-53. doi: 10.3109/10408410903241444.
8
Acquisition of flucytosine, azole, and caspofungin resistance in Candida glabrata bloodstream isolates serially obtained from a hematopoietic stem cell transplant recipient.光滑念珠菌血流分离株在造血干细胞移植受者体内连续获得氟胞嘧啶、唑类和卡泊芬净耐药性。
Antimicrob Agents Chemother. 2010 Mar;54(3):1360-2. doi: 10.1128/AAC.01138-09. Epub 2009 Dec 28.
9
A global evaluation of voriconazole activity tested against recent clinical isolates of Candida spp.针对近期念珠菌属临床分离株对伏立康唑活性的全球评估
Diagn Microbiol Infect Dis. 2009 Feb;63(2):233-6. doi: 10.1016/j.diagmicrobio.2008.11.001. Epub 2008 Dec 12.
10
Development of caspofungin resistance following prolonged therapy for invasive candidiasis secondary to Candida glabrata infection.光滑念珠菌感染继发侵袭性念珠菌病长期治疗后卡泊芬净耐药性的产生。
Antimicrob Agents Chemother. 2008 Oct;52(10):3783-5. doi: 10.1128/AAC.00473-08. Epub 2008 Aug 1.

地理分布的差异和棘白菌素类与唑类抗真菌药物耐药率在血流感染念珠菌分离株中的表现：来自 SENTRY 抗菌药物监测计划的报告（2008 年至 2009 年）。

Geographic variations in species distribution and echinocandin and azole antifungal resistance rates among Candida bloodstream infection isolates: report from the SENTRY Antimicrobial Surveillance Program (2008 to 2009).

机构信息

JMI Laboratories, 345 Beaver Kreek Centre, North Liberty, Iowa 52317, USA.

出版信息

J Clin Microbiol. 2011 Jan;49(1):396-9. doi: 10.1128/JCM.01398-10. Epub 2010 Nov 10.

DOI:10.1128/JCM.01398-10
PMID:21068282
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3020436/
Abstract

Antifungal testing results from the SENTRY Antimicrobial Surveillance Program (2008 to 2009) were analyzed for regional variations of invasive Candida species infections. Among 2,085 cases from the Asian-Pacific (APAC) (51 cases), Latin American (LAM) (348 cases), European (EU) (750 cases), and North American (NAM) (936 cases) regions, Candida albicans predominated (48.4%), followed by C. glabrata (18.0%), C. parapsilosis (17.2%), C. tropicalis (10.5%), and C. krusei (1.9%). Resistance to echinocandins (anidulafungin [2.4%] and micafungin [1.9%]) and azoles (3.5 to 5.6%) was most prevalent among C. glabrata isolates, as determined using recently established CLSI breakpoint criteria. C. glabrata isolates were more common in NAM (23.5%), and C. albicans isolates were more common in APAC (56.9%), with C. parapsilosis (25.6%) and C. tropicalis (17.0%) being more prominent in LAM. Emerging resistance patterns among C. glabrata cases in NAM require focused surveillance.

摘要

对 2008 年至 2009 年 SENTRY 抗菌监测计划（SENTRY Antimicrobial Surveillance Program）的抗真菌检测结果进行了分析，以了解侵袭性念珠菌属物种感染的地域差异。在亚太地区（APAC）（51 例）、拉丁美洲（LAM）（348 例）、欧洲（EU）（750 例）和北美（NAM）（936 例）的 2085 例病例中，白念珠菌（Candida albicans）占优势（48.4%），其次是近平滑念珠菌（C. glabrata）（18.0%）、近平滑念珠菌（C. parapsilosis）（17.2%）、热带念珠菌（C. tropicalis）（10.5%）和克柔念珠菌（C. krusei）（1.9%）。根据最近建立的 CLSI 折点标准，在白念珠菌中，棘白菌素（anidulafungin [2.4%] 和米卡芬净 [1.9%]）和唑类药物（3.5 至 5.6%）的耐药性最为常见。光滑念珠菌（C. glabrata）分离株在 NAM 更为常见（23.5%），而白念珠菌（C. albicans）分离株在 APAC 更为常见（56.9%），近平滑念珠菌（C. parapsilosis）（25.6%）和热带念珠菌（C. tropicalis）（17.0%）在 LAM 更为常见。在 NAM 中，C. glabrata 病例中出现的耐药模式需要重点监测。